Astrocytoma

These findings will not only aid in understanding the mechanisms by which EV71 infection impacts the host immune system but also provide a scientific basis for identifying early diagnostic biomarkers and developing new therapeutic strategies.

IDH1-vac-induced T cell responses were detected in the inflamed brain lesion of an IDH1-vac-associated pseudoprogression, whereas no IDH1-vac-induced T cells were found in participants with early progressive disease. The favorable long-term outcome of the NOA16 cohort supports investigating IDH1-vac in persons with newly diagnosed grade 3 and 4 (World Health Organization classification 2021) IDH-mutant astrocytomas in a randomized phase 2 trial (ClinicalTrials.gov identifier: NCT02454634 ).

Hypoxia and chemokine signaling emerged as key components of the glioma-immune landscape that evolve with tumor progression. These findings identify potential therapeutic opportunities in PXA, and they argue that optimal immunomodulatory strategies in glioma will differ along the disease trajectory.

High ALKBH2 expression in chemotherapy-treated IDH-wild-type glioma and low LMO7 expression in the CGGA astrocytoma cohort are each associated with shorter overall survival. Together, these results indicate that oxidative stress-coupled LMO7-dependent polyubiquitination of ALKBH2 modulates TMZ sensitivity in GBM, particularly in MGMT-deficient tumors.

The findings of this study suggest that PDD may be less effective in the surgery of astrocytic tumors of the spinal cord compared with those of the brain. Verifying the molecular differences of astrocytic tumors between the spinal cord and brain in a large number of cases will be necessary in future studies.

P1/2, N=58, Active, not recruiting, Queensland Institute of Medical Research | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Oct 2025

We report 10-years old child with recurrent PA harboring concurrent BRAFV600E and TP53 mutations, emphasizing the potential biological significance of this dual-mutant genotype. This case supports the growing recognition that specific molecular variants may identify children at increased risk of early tumor regrowth despite initial gross total resection.

P2, N=120, Active, not recruiting, NRG Oncology | Trial completion date: Jun 2027 --> Jul 2026

P1/2, N=33, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting

Both LAK and CIK therapies could be beneficial for glioma patients, with CIK being safer and associated with higher efficacy. Although larger clinical trials are needed to consolidate observed outcomes.

Correlation with lipogenic activation of sterol response element (SRE) in hepatocarcinoma cells, was more complex. CRT response was diverse revealing ligands with theoretical full agonist, partial agonist, antagonist, inverse agonist, and other signatures within the same chemical series, suggesting the scope for precision CRT to guide nonlipogenic LXR agonist design.